Phaseline

Companies › UCB BIOSCIENCES

UCB BIOSCIENCES: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Psychiatry; next expected readout Feb 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
fenfluramine hydrochloride
Serotonin 1d (5-HT1d) receptor agonist; Serotonin 2c (5-HT2c) receptor agonist; Sigma opioid receptor antagonist
HTR1D, HTR2C, SIGMAR1Phase 3Rett SyndromeFeb 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07503444fenfluramine hydrochloridePhase 3Rett SyndromePsychiatryFeb 2029

Targets

HTR1D (1) HTR2C (1) SIGMAR1 (1)

Companies with the same targets

Zogenix Exciva Technophage Boryung Pharmaceutical Tonix Pharmaceuticals Anavex Life Sciences Pentixapharm CSPC Ouyi Pharmaceutical

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.